Pharma Equity Group AS (OCSE:PEG) ROC (Joel Greenblatt) %: -7,838.16% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Pharma Equity Group AS ROC (Joel Greenblatt) %?

Pharma Equity Group AS OCSE:PEG -0.94% ROC (Joel Greenblatt) % is -7,838.16% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 1,322 Biotechnology companies, Pharma Equity Group AS ranks worse than 87.59% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Pharma Equity Group AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -7,838.16%.

The historical rank and industry rank for Pharma Equity Group AS's ROC (Joel Greenblatt) % or its related term are showing as below:

OCSE:PEG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9643.76   Med: -406.62   Max: 0.77
Current: -6811.51

During the past 13 years, Pharma Equity Group AS's highest ROC (Joel Greenblatt) % was 0.77%. The lowest was -9643.76%. And the median was -406.62%.

OCSE:PEG's ROC (Joel Greenblatt) % is ranked worse than
87.59% of 1322 companies
in the Biotechnology industry
Industry Median: -297.06 vs OCSE:PEG: -6811.51

Pharma Equity Group AS's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Pharma Equity Group AS  (OCSE:PEG) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Pharma Equity Group AS ROC (Joel Greenblatt) % Related Terms


Pharma Equity Group AS ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Pharma Equity Group AS's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Equity Group AS ROC (Joel Greenblatt) % Chart

Pharma Equity Group AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -4,934.32 -9,643.76 -5,261.96

Pharma Equity Group AS Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -117.91 -5,216.96 -15,647.95 -8,269.57 -7,838.16

OCSE:PEG vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Pharma Equity Group AS's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group AS ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group AS's ROC (Joel Greenblatt) % falls into.



Pharma Equity Group AS ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.736) - (3.879 + 0 + 0.589)
=-1.732

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.875) - (3.875 + 0 + 1.495)
=-1.495

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Pharma Equity Group AS for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-30.608/( ( (0.144 + max(-1.732, 0)) + (0.637 + max(-1.495, 0)) )/ 2 )
=-30.608/( ( 0.144 + 0.637 )/ 2 )
=-30.608/0.3905
=-7,838.16 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -7,838.16% mean?
Pharma Equity Group AS (OCSE:PEG) has a ROC (Joel Greenblatt) % of -7,838.16% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Pharma Equity Group AS and its competitors. According to the industry distribution chart, Pharma Equity Group AS ranks #1158 out of 1322 companies in the Biotechnology industry, placing it in the top 87.6%.
Is Pharma Equity Group AS's ROC (Joel Greenblatt) % too high?
Pharma Equity Group AS's current ROC (Joel Greenblatt) % is -7,838.16%. Based on the distribution chart, Pharma Equity Group AS ranks #1158 out of 1322 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Pharma Equity Group AS's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Equity Group AS ranks #1158 out of 1322 companies for ROC (Joel Greenblatt) %. This places Pharma Equity Group AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Pharma Equity Group AS and its competitors. Pharma Equity Group AS's current ROC (Joel Greenblatt) % is -7,838.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current ROC (Joel Greenblatt) % of -7,838.16%. The current ROC (Joel Greenblatt) % is -7,838.16%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current ROC (Joel Greenblatt) % is -7,838.16% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharma Equity Group AS Business Description

Address Slotsmarken 12, 1.th, Horsholm, DNK, DK-2970
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .